Vaccine signatures in humanized mice point to better understanding of infectious diseases

Now a team at Princeton University has developed a comprehensive way to evaluate how immune responses of humanized mice measure up to actual humans. The research team looked at the mouse and human immune responses to one of the strongest vaccines known, a yellow fever vaccine called YFV-17D. The comparison of these "vaccine signatures" showed that a newly developed humanized mouse developed at Princeton shares significant immune-system responses with humans. The study was published in the journal Nature Communications.

"Understanding immune responses to human pathogens and potential vaccines remains challenging due to differences in the way our human immune system responds to stimuli, as compared to for example that of conventional mice, rats or other animals," said Alexander Ploss, associate professor of molecular biology at Princeton University. "Until now a rigorous method for testing the functionality of the human immune system in such a model has been missing. Our study highlights an experimental paradigm to address this gap."

Humanized mice have been used in infectious disease research since the late 1980s. Yet without rigorous comparisons, researchers know little about how well the mice predict human responses such as the production of infection-fighting cells and antibodies.

To address this issue, researchers exposed the mice to the YFV-17D vaccine, which is made from a weakened, or attenuated, living yellow fever virus. Vaccines protect against future infection by provoking the production of antibodies and immune-system cells.

In previous work, the researchers explored the effect of YFV-17D on conventional humanized mice. But the researchers found that the mice responded only weakly. This led them to develop a mouse with responses that are more similar to those of humans.

To do so, the researchers introduced additional human genes for immune system components -- such as molecules that detect foreign invaders and chemical messengers called cytokines -- so that the complexity of the engrafted human immune system reflected that of humans. They found that the new mice have responses to YFV-17D that are very similar to the responses seen in humans. For example, the pattern of gene expression that occurs in response to YFV-17D in the mice shared significant similarities to that of humans. This signature gene expression pattern, reflected in the "transcriptome," or total readout of all of the genes of the organism, translated into better control of the yellow fever virus infection and to immune responses that were more specific to yellow fever.

"Many vaccines have been generated empirically without profound knowledge of how they induce immunity," Douam said. "The next generation of mouse models, such as the one we introduced in our study, offer unprecedented opportunities for investigating the fundamental mechanisms that define the protective immunity induced by live-attenuated vaccines."

Mice bearing human cells or human tissues have the potential to aid research on treatments for many diseases that infect humans but not other animals, such as -- in addition to HIV -- Epstein Barr Virus, human T-cell leukemia virus, and Karposi sarcoma-associated herpes virus.

"Our study highlights the importance of human biological signatures for guiding the development of mouse models of disease," said Ploss. "It also highlights a path toward developing better models for human immune responses."

The study involved contributions from Florian Douam, Carly G. K. Ziegler, Gabriela Hrebikova, Bruno Fant, Robert Leach, Lance Parsons, Wei Wang, Jenna M. Gaska, Benjamin Y. Winer, Brigitte Heller, Alex K. Shalek and Alexander Ploss.

Funding for this study was provided by the National Institutes of Health, the National Institute of General Medical Sciences, the Bill & Melinda Gates Foundation and the New Jersey Commission on Cancer Research.